Myriad Genetics’ MYGN strong product portfolio raises our optimism. The company’s impressive growth strategy also encourages us. However, macroeconomic issues impede growth. The stock carries a Zacks ...
Source LinkMyriad Genetics’ MYGN strong product portfolio raises our optimism. The company’s impressive growth strategy also encourages us. However, macroeconomic issues impede growth. The stock carries a Zacks ...
Source Link
Comments